Podcast Episodes
Back to Search
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions
Episode 206
In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metasta…
Published on 2 months, 1 week ago
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
Episode 208
In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:
The clin…Published on 2 months, 3 weeks ago
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
Episode 207
In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients wi…
Published on 2 months, 3 weeks ago
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025
Episode 205
In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and IC…
Published on 3 months, 1 week ago
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting
Episode 204
In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including:
DESTINY-…Published on 3 months, 1 week ago
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC
Episode 203
In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients w…
Published on 3 months, 1 week ago
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
Episode 202
In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments…
Published on 3 months, 1 week ago
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
Episode 201
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and…
Published on 3 months, 2 weeks ago
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Episode 199
In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC includ…
Published on 3 months, 2 weeks ago
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies
Episode 200
In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing …
Published on 3 months, 2 weeks ago